Table 6.
Antibody | Cells
|
|||
---|---|---|---|---|
HUVE
|
HME
|
|||
[3H]thymidine incorporation, cpm | % increase | [3H]thymidine incorporation, cpm | % increase | |
Control | ||||
− | 4,400 ± 200 | 100 | 9,700 ± 300 | 100 |
+ | 5,900 ± 50 | 134 | 12,000 ± 300 | 124 |
aFGF IgG | ||||
− | 5,100 ± 100 | 100 | 10,500 ± 400 | 100 |
+ | 5,800 ± 100 | 114 | 12,100 ± 500 | 115 |
bFGF IgG | ||||
− | 3,400 ± 600 | 100 | 5,900 ± 300 | 100 |
+ | 4,100 ± 500 | 121 | 7,500 ± 400 | 127 |
aFGF IgG plus | ||||
bFGF IgG | ||||
− | 3,000 ± 200 | 100 | 5,900 ± 800 | 100 |
+ | 3,900 ± 100 | 130 | 8,100 ± 400 | 137 |
HUVE and HME cells were plated at 1.6 × 104 cells per well in 24-well plates (8 × 103 cells per cm2). Concentrations of angiogenin, anti-aFGF, and anti-bFGF antibody were 1, 10, and 10 μg/ml, respectively. −, Absence of angiogenin; +, presence of angiogenin.